Skip to content
HowShorted

Virpax Pharmaceuticals, Inc. short interest in 2022

In 2022, Virpax Pharmaceuticals, Inc.'s disclosed short interest ran from 0.53% of shares outstanding on 31 Mar 2022 to 0.36% on 30 Dec 2022, a change of -0.17 percentage points. The year's high was 1.15% on 13 May 2022 and its low 0.22% on 14 Oct 2022, averaging 0.49% across 19 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 2.74 days on 15 Dec 2022. Full history: Virpax Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024

Aggregate net short position time series for Virpax Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
0.53% (31 Mar 2022)
End of year
0.36% (30 Dec 2022)
Change
-0.17 pp
High
1.15% (13 May 2022)
Low
0.22% (14 Oct 2022)
Average
0.49%
Highest days to cover
2.74 (15 Dec 2022)
SEC filings marked
8

Every report in 2022

Virpax Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
31 Mar 20220.53%1.0010-K filed, results (8-K)
14 Apr 20220.70%1.00
29 Apr 20220.71%1.00
13 May 20221.15%1.00
31 May 20220.75%1.0010-Q filed, results (8-K)
15 Jun 20220.65%1.21
30 Jun 20220.55%1.00
15 Jul 20220.33%1.00
29 Jul 20220.58%2.16
15 Aug 20220.32%1.0010-Q filed, results (8-K)
31 Aug 20220.25%1.00
15 Sep 20220.26%1.00
30 Sep 20220.36%1.80
14 Oct 20220.22%1.26
31 Oct 20220.25%1.00
15 Nov 20220.30%1.0010-Q filed, results (8-K)
30 Nov 20220.36%1.15
15 Dec 20220.73%2.74
30 Dec 20220.36%1.00

See also: Virpax Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.